Literature DB >> 8408134

Ewing sarcoma of the pelvis. Clinicopathological features and treatment.

F J Frassica1, D A Frassica, D J Pritchard, P J Schomberg, L E Wold, F H Sim.   

Abstract

The results of treatment in twenty-seven patients who had a Ewing sarcoma of the pelvis were reviewed. Six patients had had metastatic disease at the time of the diagnosis. The three-year actuarial survival of these patients was 17 per cent (95 per cent confidence interval, 8 to 52 per cent). Of the twenty-one remaining patients, thirteen had received chemotherapy and radiation therapy to the primary lesion and eight had had chemotherapy and operative resection, with or without radiation therapy. The actuarial five-year over-all survival was 25 per cent (95 per cent confidence interval, 6 to 51 per cent) in the group that had had radiation without a resection and 75 per cent (95 per cent confidence interval, 31 to 93 per cent) in the group that had had a resection (p < 0.005, log-rank method). The actuarial over-all five-year survival was 45 per cent (23 to 65 per cent) for all patients who had had localized disease when first seen. Actuarial local failure analysis (the censoring of patients who died without evidence of local failure before the two-year follow-up examination) revealed a rate of local failure of 44 per cent (14 to 79 per cent) in the group that had been treated with chemotherapy and radiation alone compared with 13 per cent (0 to 53 per cent) in the patients who had had a resection, but this difference was not significant (p > 0.25, log-rank method).(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1993        PMID: 8408134     DOI: 10.2106/00004623-199310000-00006

Source DB:  PubMed          Journal:  J Bone Joint Surg Am        ISSN: 0021-9355            Impact factor:   5.284


  15 in total

1.  Long-lasting multiagent chemotherapy in adult high-risk Ewing's sarcoma of bone.

Authors:  Selmin Ataergin; Ahmet Ozet; Luis Solchaga; Mustafa Turan; Murat Beyzadeoglu; Kaan Oysul; Fikret Arpaci; Seref Komurcu; Serdar Surenkok; Mustafa Ozturk
Journal:  Med Oncol       Date:  2008-11-07       Impact factor: 3.064

2.  Misdiagnosis of Ewing's sarcoma of the ilium at the pelvis X-ray.

Authors:  Francesco De Maddi; Donato Rigante; Rosaria de Ritis; Emanuela Sacco; Paolo Siani
Journal:  Rheumatol Int       Date:  2011-03-25       Impact factor: 2.631

3.  EWS-Fli1 antisense oligodeoxynucleotide inhibits proliferation of human Ewing's sarcoma and primitive neuroectodermal tumor cells.

Authors:  K Tanaka; T Iwakuma; K Harimaya; H Sato; Y Iwamoto
Journal:  J Clin Invest       Date:  1997-01-15       Impact factor: 14.808

4.  Surgical complications after preoperative irradiation of Ewing's sarcoma.

Authors:  A Hillmann; T Ozaki; C Rübe; C Hoffmann; A Schuck; S Blasius; A Haas; H Jürgens; W Winkelmann
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

5.  Surgical management of pelvic Ewing's sarcoma.

Authors:  Mayil Vahanan Natarajan; M Mohamed Sameer; Jagdish Chandra Bose; Kunal Dheep
Journal:  Indian J Orthop       Date:  2010-10       Impact factor: 1.251

Review 6.  Common musculoskeletal tumors of childhood and adolescence.

Authors:  Carola A S Arndt; Peter S Rose; Andrew L Folpe; Nadia N Laack
Journal:  Mayo Clin Proc       Date:  2012-05       Impact factor: 7.616

7.  [Surgical therapy of pelvis and spine in primary malignant bone tumors].

Authors:  R Windhager; H Welkerling; N Kastner; P Krepler
Journal:  Orthopade       Date:  2003-11       Impact factor: 1.087

8.  Should Aggressive Surgical Local Control Be Attempted in All Patients with Metastatic or Pelvic Ewing's Sarcoma?

Authors:  Steven W Thorpe; Kurt R Weiss; Mark A Goodman; Alma E Heyl; Richard L McGough
Journal:  Sarcoma       Date:  2012-03-04

9.  Ten-Year Follow-Up of a Patient with Metastatic Ewing's Sarcoma of the Pelvis.

Authors:  Robert U Ashford; Eugene V McCloskey; O Prakash Purohit; Christine E Ingram; Robert J Grimer; Robert E Coleman
Journal:  Sarcoma       Date:  2002

Review 10.  Medication Exposures and Subsequent Development of Ewing Sarcoma: A Review of FDA Adverse Event Reports.

Authors:  Judith U Cope; Gregory H Reaman; Joseph M Tonning
Journal:  Sarcoma       Date:  2015-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.